Extensively Drug-Resistant Shigellosis: US Trends and Risks

This site is intended for healthcare professionals

Extensively Drug-Resistant Shigellosis Surges Across the US

Author:
Men are standing in front of the bathroom door using their hands to hold the abdomen with severe abdominal pain or diarrhea.

Key Summary:

  • XDR Shigella isolates in the US rose from 0% between 2011 and 2015 to 8.5% of tested samples in 2023.
  • Adult men represented over 86% of cases, signaling an epidemiologic pivot away from young children.
  • Over 37% of patients were hospitalized, and no FDA-approved oral therapies exist to manage infections.

EXTENSIVELY drug-resistant shigellosis has escalated significantly across the United States, shifting primary disease to adult men. Surveillance analysis of nearly 17,000 bacterial isolates submitted to the national molecular network revealed that the proportion of extensively drug-resistant cases expanded from 0% between 2011 and 2015 to 8.5% by late 2023. These isolates demonstrate co-resistance to all frontline oral agents, including ampicillin, azithromycin, ceftriaxone, ciprofloxacin, and trimethoprim-sulfamethoxazole, leaving clinicians without Food and Drug Administration approved oral therapies.

Epidemiologic Shift Toward Adult Demographics and Comorbidities

Historically regarded as a pediatric diarrheal infection primarily affecting child care attendees, recent trends demonstrate a stark epidemiologic pivot within infectious diseases. Among patients with extensively drug-resistant shigellosis, 96.1% were adults with a median age of 41 years, and 86.2% were men. Furthermore, 46.6% of patients with known status presented with HIV co-infection, highlighting severe vulnerability among immunocompromised individuals. Notably, 82.4% of patients reported no recent international travel, confirming sustained domestic community transmission across urban networks rather than isolated travel associated cases.

Clinical Challenges in Managing Extensively Drug-Resistant Shigellosis

Clinical severity remains substantial, with 37.6% of evaluated patients requiring inpatient hospitalization. Although Shigella sonnei caused 65.9% of resistant episodes, Shigella flexneri accounted for 34.1% of resistant isolates, which is nearly double its historical prevalence in general surveillance. This species distribution raises major clinical concern because Shigella flexneri is closely linked to mucosal ulceration, bloody dysentery, and prolonged disease. Furthermore, approximately one-third of resistant isolates showed co-resistance to chloramphenicol. Given that no oral agents possess regulatory clearance for this pathogen, hospital teams face complex decisions in routine clinical practice when managing systemic infection.

To prevent widespread enteric outbreaks, clinicians must prioritize diagnostic stool cultures alongside whole-genome sequencing rather than relying solely on rapid panels. Early identification allows medical teams to detect resistant lineages, optimize infection control protocols, and avoid ineffective empiric regimens. Enhanced awareness and swift susceptibility testing remain critical to curbing extensively drug-resistant shigellosis across vulnerable populations throughout the country.

Reference

Logan N et al. Emergence of Extensively Drug-Resistant Shigellosis — United States, 2011–2023. MMWR Morb Mortal Wkly Rep. 2026;75(13):173-178.

Shisu_ka on adobe stock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.